Hypoparathyroidism - Pipeline Review, H1 2018 - Product Image

Hypoparathyroidism - Pipeline Review, H1 2018

  • ID: 4542966
  • Report
  • 49 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Ascendis Pharma A/S
  • Eli Lilly and Co
  • Entera Bio Ltd
  • GC Pharma
  • Shire Plc
  • MORE
Hypoparathyroidism - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism - Pipeline Review, H1 2018, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape.

Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction), and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes artificial form of the hormone that can be administered as replacement, calcium replacement or vitamin.

Report Highlights:

This latest pipeline guide Hypoparathyroidism - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hypoparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 3 and 4 respectively.

Hypoparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoparathyroidism (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypoparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypoparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypoparathyroidism (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypoparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Ascendis Pharma A/S
  • Eli Lilly and Co
  • Entera Bio Ltd
  • GC Pharma
  • Shire Plc
  • MORE
Introduction

Report Coverage

Hypoparathyroidism - Overview

Hypoparathyroidism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hypoparathyroidism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypoparathyroidism - Companies Involved in Therapeutics Development

Ascendis Pharma A/S

Chugai Pharmaceutical Co Ltd

Eli Lilly and Co

Entera Bio Ltd

GC Pharma

Shire Plc

Hypoparathyroidism - Drug Profiles

ACP-014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EB-612 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXT-601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-6272K - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

parathyroid hormone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PCO-371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem cell Therapy for Hypoparathyroidism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypoparathyroidism - Dormant Projects

Hypoparathyroidism - Product Development Milestones

Featured News & Press Releases

May 07, 2018: Ascendis Pharma Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology

Apr 09, 2018: Shire’s Natpar Rejects For Use Within NHS Scotland

Mar 20, 2018: New Data Presented at the Endocrine Society’s 2018 Annual Meeting Advances Understanding of the Rare Disease Chronic Hypoparathyroidism

Mar 19, 2018: Ascendis Pharma Announces Posters on Rare Disease Pipeline Programs at ENDO 2018

Mar 12, 2018: Shire to Highlight Advancements in Chronic Hypoparathyroidism Research at the Endocrine Society’s 2018 Annual Meeting

Jan 08, 2018: Ascendis Pharma Provides Update on Rare Disease Endocrinology Pipeline and Presents Initial Phase 1 Data for TransCon PTH

Sep 26, 2017: Ascendis Pharma Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH

Sep 05, 2017: Ascendis Pharma Announces Presentations on TransCon PTH at Upcoming Medical Conferences

May 19, 2017: Shire to highlight new research into chronic hypoparathyroidism at the European Congress of Endocrinology

Apr 26, 2017: Shire Granted EU Conditional Marketing Authorisation for Natpar (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism

Apr 03, 2017: Ascendis Pharma Presents Data on TransCon PTH at ENDO

Feb 28, 2017: Ascendis Pharma Announces Data on TransCon PTH at ENDO

Feb 24, 2017: First hormone replacement therapy for parathyroid disorder

Jun 29, 2016: EnteraBio Receives Orphan Drug Approval for PTH 1-34 from European Medicines Agency

Jul 22, 2015: Entera Bio Announces Phase II Results of PTH 1-34 in Treating Hypoparathyroidism

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hypoparathyroidism, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Hypoparathyroidism - Pipeline by Ascendis Pharma A/S, H1 2018

Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

Hypoparathyroidism - Pipeline by Eli Lilly and Co, H1 2018

Hypoparathyroidism - Pipeline by Entera Bio Ltd, H1 2018

Hypoparathyroidism - Pipeline by GC Pharma, H1 2018

Hypoparathyroidism - Pipeline by Shire Plc, H1 2018

Hypoparathyroidism - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Hypoparathyroidism, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Ascendis Pharma A/S
  • Chugai Pharmaceutical Co Ltd
  • Eli Lilly and Co
  • Entera Bio Ltd
  • GC Pharma
  • Shire Plc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll